Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

Stock Information for Kadmon Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kadmon Holdings Inc.

Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings
Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan
Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Kadmon to Participate in Upcoming Investor Conferences
Kadmon Announces Pricing of Public Offering of Common Stock
Kadmon Announces Proposed Public Offering of Common Stock
Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China
Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.